Summit Therapeutics (SMMT) Debt to Equity (2022 - 2024)
Summit Therapeutics' Debt to Equity history spans 3 years, with the latest figure at $2.26 for Q1 2024.
- For Q1 2024, Debt to Equity rose 201.93% year-over-year to $2.26; the TTM value through Mar 2024 reached $2.26, up 201.93%, while the annual FY2023 figure was $1.29, 67.04% down from the prior year.
- Debt to Equity reached $2.26 in Q1 2024 per SMMT's latest filing, up from $1.29 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $3.9 in Q4 2022 to a low of $0.39 in Q1 2022.
- Average Debt to Equity over 3 years is $1.42, with a median of $0.84 recorded in 2023.
- Peak YoY movement for Debt to Equity: tumbled 67.04% in 2023, then surged 201.93% in 2024.
- A 3-year view of Debt to Equity shows it stood at $3.9 in 2022, then crashed by 67.04% to $1.29 in 2023, then surged by 75.73% to $2.26 in 2024.
- Per Business Quant, the three most recent readings for SMMT's Debt to Equity are $2.26 (Q1 2024), $1.29 (Q4 2023), and $0.84 (Q2 2023).